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Abstract 
 
The toxicity of platinum anticancer drugs presents a major obstacle in the effective 
treatment of tumours. Much of the toxicity stems from a lack of specificity of the 
drugs for the sites at which they are able to exert maximum anticancer activity. An 
improved understanding of the behaviour of the drugs in the tumour environment 
may assist in the rational design of future platinum anticancer agents with enhanced 
specificity and reduced toxicity. In the work presented herein, the specificity of two 
classes of platinum anticancer agents was assessed (platinum(IV) cisplatin 
analogues and platinum(II) anthraquinone complexes).  
 
The interaction of the platinum(IV) agents with DNA, believed to be their main cellular 
target, was examined using XANES spectroscopy. This experiment was designed to 
assess the ability of the drugs to interact with DNA and thus exert their anticancer 
activity. It was shown that the platinum(IV) complexes were not reduced by DNA 
during 48 hr incubation. It was not possible to conclusively determine whether the 
interaction of the complexes with DNA was direct or platinum(II) catalysed, or 
whether interaction had occurred at all. 
 
The distribution of platinum(II) anthraquinone complexes and their corresponding 
anthraquinone ligands in tumour cells (A2780 ovarian and DLD-1 colon cancer cell 
lines) was investigated. The cytotoxicity of the compounds in DLD-1 cells was also 
assessed. It was found that the compounds were efficiently taken up into the cells 
and entered the lysosomal compartments almost exclusively. This suggested that the 
cytotoxicity of the drugs was caused by lysosomal disruption, or that the platinum 
complexes were degraded, leaving a platinum species to enter the cell nuclei and 
interact with DNA. Alternatively, the complexes may bind to proteins and transport 
into the nuclei of the cells, though with their fluorescence quenched by the protein.    
 
The penetration and distribution of platinum(IV) complexes was assessed in DLD-1 
multicellular tumour spheroids (established models of solid tumours) using a number 
  v  
of synchrotron techniques, including micro-tomography, micro-SRIXE, and micro-
XANES. The complexes were found to be capable of penetrating throughout the entire 
volume of the spheroids. Micro-XANES indicated that in central and peripheral 
spheroidal regions, bound platinum species were present largely as platinum(II). 
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1.1 Existing platinum-based anticancer therapies 
 
Existing anticancer therapies have limited selectivity for tumour tissue compared to 
healthy tissue. This causes adverse side-effects for the patient and limits the dose 
able to be administered. Sequence and structural differences between healthy and 
cancerous DNA are anticipated to emerge in the near future as a consequence of the 
human genome mapping project.1 By taking advantage of the unique characteristics 
of DNA found in tumours, anticancer drugs could be selectively targeted to tumours, 
potentially minimising adverse side effects. 
 
1.2 Platinum anticancer drugs 
 
Platinum complexes currently make up one of the three most widely used groups of 
anticancer drugs in the world.2, 3 The anticancer activity of cisplatin (cis-[PtCl2(NH3)2], 
see Figure 1.1, (1)) was discovered serendipitously in the 1960s.4 Since 1978 it has 
been used in the clinic against a variety of cancers, including testicular, ovarian, 
head and neck, bladder, cervical, lymphoma and melanoma. Treatment with cisplatin 
often causes severe side effects such as nausea, vomiting, nephrotoxicity, 
neurotoxicity, myelotoxicity, and emetogenesis.2 These side effects arise mainly as a 
result of the limited selectivity of cisplatin for tumour cells as compared to healthy 
cells,5 and may also be due to reactions with thiol-containing species in blood 
plasma, such as cysteine and human serum albumin.6-11 In spite of its widespread 
clinical use, many tumours are unresponsive to cisplatin treatment due to intrinsic 
(eg. colon cancer, non-small-cell lung cancer) or acquired resistance (eg. ovarian 
cancer, small-cell lung cancer).12 The cellular mechanisms of cisplatin resistance 
have been identified and recently reviewed. 13-16 The main factors that modulate 
resistance include decreased drug accumulation, increased levels of intracellular 
thiols that can deactivate cisplatin, and an increased capability of cells to repair or 
tolerate DNA damage caused by cisplatin. Other processes have also been 
implicated.  
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Figure 1.1: Structures of cisplatin (1), carboplatin (2) and oxaliplatin (3). 
 
The search for platinum anticancer drugs with improved activity and selectivity, 
minimal side effects and circumvention of cisplatin resistance has produced 
thousands of complexes; of which few significantly improve upon the performance of 
cisplatin. This is reflected in the fact that less than 1% of such complexes have 
entered clinical trials.17 Carboplatin, cis-[Pt(NH3)2(CBDCA)] where CBDCA = 1,1-
cyclobutanedicarboxylic acid (see Figure 1.1, (2)), has achieved widespread clinical 
approval.2, 18 It has the advantage of being less toxic than cisplatin, although it is only 
effective against the same range of tumours.2 Oxaliplatin ([Pt(oxalato)(1R,2R-chxn)], 
chxn = cyclohexane-1,2-diamine, see Figure 1.1, (3)) was approved in France, the UK 
and other European countries in 1996 and in the US in 2002 for clinical use against 
advanced colorectal cancer2, 19, 20; and is the only platinum complex to have 
displayed activity against colorectal cancer thus far.20 In spite of these successes, 
the toxicity, limited spectrum of activity, and resistance of such drugs remain 
significant obstacles to overcome. 
 
1.3 Platinum(IV) complexes 
 
The majority of platinum drugs studied have been in the platinum(II) oxidation state. 
More recently there has been increasing interest in the use of platinum(IV) 
complexes.21, 22 Platinum(IV) drugs are thought to hold substantial promise due to 
their relatively low reactivity, which should enable the drug to arrive at the tumour 
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site intact, reducing the incidence of side reactions, and hence minimising the toxic 
side effects associated with chemotherapy. The axial functional groups may endow 
the complex with a lipophilic nature, that when combined with the low reactivity of 
platinum(IV) species should enhance the cellular uptake of such drugs.22 
Platinum(IV) complexes are believed to act as prodrugs, requiring reduction to their 
active platinum(II) analogues prior to exerting anticancer activity.2, 23 As such, the 
reduction potential of platinum(IV) complexes is expected to influence their biological 
activity.22, 24 
 
In vitro studies involving platinum(IV) complexes have produced some promising 
results. Kelland et al25 studied the in vitro cytotoxicity of numerous ammine/amine 
platinum(IV) trans-dicarboxylate species (analogues of satraplatin, a complex 
currently undergoing Phase 3 clinical trials) against human ovarian carcinoma cell 
lines with cisplatin resistance of varying degrees. A number of these complexes 
displayed cytotoxicities up to 840 times that of cisplatin, with significant selectivity 
towards the most resistant cell lines. The highest cytotoxicity was displayed by the 
most lipophilic species. This has been attributed to the ease of entry of the 
complexes into cells where they undergo reduction to the active platinum(II) 
species.25 
 
A similar study was performed by Jolley and coworkers.26 The platinum(IV) species 
investigated (analogues of satraplatin) consisted of ethane-1,2-diamine derived 
ligands containing alcohol, carboxylic acid, and acetate substituents. The in vitro 
cytotoxicity of these complexes was considerably poorer than that of the complexes 
studied by Kelland.25, 26 This was thought to be due to their relatively low lipophilicity 
and/or the negative charge of the corresponding platinum(II) complex, which may 
cause repulsion with the DNA phosphodiester backbone.26 
 
Rationally designed platinum(IV) agents have been developed and tested in recent 
years. Such agents often possess substituents designed to improve the selectivity of 
the drug. For example, Kratochwil et al have developed analogues of satraplatin, 
containing iodo ligands. Irradiation of such complexes with visible light was found to 
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induce non-reversible binding to DNA,27 stereospecific reactions with 5’-GMP28, and 
cytotoxicity. One such complex displayed 35 % greater growth inhibitory activity in 
vitro in human bladder cancer cells when irradiated with light during the first 1.5 hr of 
drug exposure compared to the equivalent sample that remained in the dark.27 
Platinum(IV)-diazide compounds have been shown to display similar properties, 
although they possess better stability under physiological conditions than the iodo 
complexes.29 In addition, the platination sites of these complexes were found to be 
similar to those observed for cisplatin.30 Thus there exists the potential of 
photoactivating platinum(IV) prodrugs specifically in and around tumour sites. 
 
A novel platinum(IV) complex possessing ethacrynic acid in its axial positions has 
been developed. Ethacrynic acid (EA) is a clinically used diuretic known to inhibit 
glutathione-S-transferase (GST) isozymes that are overexpressed in cisplatin resistant 
cells lines. It was hoped that the platinum(IV) complex would be targeted to GST 
enzymes in human cancer cells and be reduced in vivo, releasing both the cytotoxic 
platinum(II) moiety, as well as the EA moiety and thus potentially showing 
effectiveness against cisplatin resistant cell lines. This complex has been shown to 
have promising cytotoxicity and the ability to inhibit GST activity to a greater extent 
than EA itself.31   
 
It is somewhat disappointing that positive results with platinum(IV) complexes have 
not yet translated into agents with significant improvements upon the clinical activity 
of cisplatin. Only a small number of platinum(IV) species have entered clinical trial in 
recent years, yet their antitumour activity remains lower than that of cisplatin and 
they have had to be withdrawn for a variety of reasons.22 The lower than expected 
clinical efficacy of platinum(IV) drugs may be due to their low reactivity with DNA, the 
efflux of platinum(IV) species from cells,32 or their rapid reduction in vivo.22, 26 
 
In an attempt to develop platinum(IV) species with a reduced rate of reduction in 
vivo, Hambley et al investigated a series of novel platinum(IV) complexes with a 
variety of reduction potentials, and moderate to high in vitro activities. Several 
difficult to reduce complexes had activities similar to the parent platinum(II) complex, 
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indicating the possibility of developing platinum(IV) complexes that possess both high 
activity and reduced side effects in humans.33  
 
Hambley and coworkers have undertaken extensive studies on a series of 
platinum(IV) complexes possessing a common platinum(II) moiety. This series 
consists of platinum(IV) analogues of cisplatin or [PtCl2(en)] with either chloro, 
acetato or hydroxo axial ligands, see Figure 1.2.  
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NH3Cl
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(4) (5) (6)
 
Figure 1.2: Structures of the platinum(IV) cisplatin analogues used by Hambley and 
coworkers. 
 
Investigation of such model complexes should aid in an improved understanding of 
the mechanism of action of platinum(IV) agents and assist in the rational design of 
future drugs. The reduction potentials of the complexes were shown to be dependent 
on the axial ligands.34 The model platinum(IV) complexes cover a relatively large 
range of reduction potentials, following the order chloro>acetato>hydroxo. A 
correlation between their reduction potentials and several of their biological 
properties has been observed. Table 1.1 shows some of these properties. In addition 
to those shown in the table, a reduction potential correlation has also been shown for 
the rate of binding of the complexes to 5’-GMP,35 and albumin, as well as protein 
binding in RPMI.11  
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Table 1.1: Biological properties of a series of platinum(IV) complexes. Reduction 
potentials (versus Ag/AgCl),32 cytotoxicity against A2780 ovarian cancer cell lines 
(µM),24, 32 platinum uptake into A2780 cells (24 hr, 30 µM),32 and proportion of 
intracellular platinum(IV) in A2780 cells following 2 hr incubation with the 
complexes.36 These properties show a close correlation to the reduction potential of 
the complexes. 
Axial group X 
(PtX(NH3)2) 
Ep (mV) IC50 (µM) 
Cell uptake 
(nmol Pt/mg 
protein) 
% Pt(IV) 
(2 hr) 
Cl2 - 2.5 2.45 1 
Cl4 -260 3.3 3.82 5 
Cl2(OAc)2 -635 17.9 0.78 33 
Cl2(OH)2 -880 22.0 0.74 54 
 
It appears the cytotoxicity of the complexes shown in Table 1.1 leaves much to be 
desired. However, it should be noted that cytotoxicity assays taken alone may be an 
inadequate basis upon which to assess the clinical efficacy of platinum(IV) agents. 
The cytotoxicity results shown in Table 1.1 suggest that difficult to reduce 
platinum(IV) complexes will be less active than complexes that are easily reduced, 
though this does not reflect clinical experience with platinum(IV) agents. For example, 
iproplatin, which has a similar reduction potential to the dihydroxo complex shown in 
Figure 1.2 (6), showed good activity in clinical trials. This suggests that a significant 
proportion of difficult to reduce platinum(IV) complexes of this type may arrive intact 
at the site of action, perhaps corresponding to fewer side reactions and hence lower 
side effects associated with treatment.24, 32 In fact, as indicated in Table 1.1, it has 
been shown that such complexes are able to enter cells as platinum(IV) and thus 
avoid deactivation in the extracellular medium. This correlated closely with reduction 
potential, with a higher percentage of platinum(IV) in cells that had been treated with 
complexes having relatively low reduction potentials.36, 37 Hence, reduction potential 
is an important property to consider in the design of future platinum(IV) therapeutics.  
 
Further inspection of Table 1.1 indicates that the cellular uptake of the platinum(IV) 
complexes is relatively low compared to cisplatin. Hall et al suggest that this may be 
because the neutral platinum(IV) complexes are able to easily diffuse in and out of 
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cells, whereas the platinum(II) complexes essentially become ‘trapped’ inside the 
cells after undergoing aquation and thus becoming positively charged species.32 
Rational design of future platinum(IV) drugs may perhaps involve inclusion of a 
functionality that would hold the agent within the cell or the tumour. 
 
1.4 DNA-Targeting 
 
Two grooves or channels are characteristic of the secondary DNA structure. These 
grooves differ significantly in size and hence are known as the major and minor 
grooves.38 The major groove has a larger number of potential hydrogen bonding sites 
than the minor groove. Hence the major groove is richer in information and is the site 
at which most sequence-selective drugs bind. Small drug molecules (<1000 Daltons) 
tend to occupy the minor groove and may also be sequence selective in nature.39 
 
Most DNA binding drugs currently in use have very little sequence selectivity. A 
number of strategies exist for increasing the selectivity of drug/DNA interactions. For 
instance, drugs may be designed to have particular characteristics that increase 
affinity for DNA. These may include the ability to take part in electrostatic 
interactions, hydrogen bonds, hydrophobic interactions, intercalative interactions, 
covalent bonds, and inert or labile coordination bonds.40-42  
 
The three main categories of drugs that interact with DNA include the alkylators, 
which form covalent bonds with DNA bases; DNA groove binders, which bind in either 
the major or minor groove by electrostatic interactions, hydrogen bonds and van der 
Waals interactions; and intercalators.39 Intercalators will be discussed further below. 
 
1.5 Intercalators 
 
Intercalators are polycyclic planar heterocycles, usually aromatic and often positively 
charged.43 Electrostatic and van der Waals interactions allow the intercalators to 
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insert between the base pairs of double-helical DNA, causing a lengthening and 
unwinding of DNA44, 45 which may prevent its replication and transcription,46 cause 
cleavage of the DNA,47 or inhibit the synthesis of DNA and RNA.48 Intercalators alone 
have little sequence selectivity, yet they bind rapidly to double-stranded DNA.49 The 
properties of intercalators can be enhanced by coupling to a moiety possessing 
sequence recognition elements. 
 
1.6 Anthraquinone intercalators 
 
The properties of anthraquinone intercalators have been extensively studied. Several 
compounds containing the anthraquinone skeleton have been found to possess good 
antitumour activity, such as doxorubicin and daunorubicin.50-55 (Figure 1.3, (7a) and 
(7b), respectively).  
 
O
O
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O
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OCH3
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O
OCH3
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2
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(7b):  R = CH
3
, daunorubicin
 
Figure 1.3:  The structures of doxorubicin (7a) and daunorubicin (7b). 
 
Daunorubicin is active against acute lymphoblastic leukemia and acute myeloblastic 
leukemia whilst doxorubicin is active against a variety of tumours such as soft-tissue 
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and osteogenic sarcomas, paediatric malignancies, leukemia, bladder, breast, lung 
and thyroid tumours.53 Clinical use of these drugs is restricted by the severe nature 
of their side effects. Both drugs cause dose-limiting myelosuppression, stomatitis, 
nausea, vomiting, alopecia, bone marrow suppression, and cumulative, irreversible 
cardiac toxicity which may cause fatal congestive heart failure.50, 52 
 
In the search for less toxic derivatives, many analogues containing the anthraquinone 
skeleton have been synthesised. Two compounds in particular have emerged as 
suitable clinical replacements: mitoxantrone and amentantrone51, 56, 57 (Figure 1.4, 
(8a) and (8b), respectively).  
 
O
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NH
NH
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X
N
H
N
H
OH
OH
(8a):  X = OH, mitoxantrone
(8b):  X = H,    ametantrone
 
 Figure 1.4:  Structures of mitoxantrone (8a) and ametantrone (8b). 
 
Mitoxantrone is effective against breast cancer, lymphoma and acute leukemia.48, 58 
It can cause myelosuppression, nausea, vomiting, stomatitis, mucositis, alopecia and 
cardiotoxicity with cumulative doses. However, the incidence of acute toxicity is 
considerably less than that caused by doxorubicin.48, 58 It is believed that 
mitoxantrone inhibits DNA and RNA synthesis.48 The interaction of mitoxantrone with 
DNA is both intercalative and non-intercalative, inducing non-protein DNA strand 
scission.48, 58 It has not been established whether the side chains reside in the major 
or minor groove when mitoxantrone is bound to DNA.59 However when the ring 
system is intercalated there is evidence to suggest that the side chains are found in 
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the major groove.59 The side chains seem to endow mitoxantrone with selectivity for 
interaction with GC-rich tracts of DNA,59, 60 and have been identified as a key factor in 
the nuclear localisation, DNA binding and inhibition of DNA synthesis.61 There is also 
evidence to suggest that the cytotoxicity of mitoxantrone is partly the result of its 
interaction with topoisomerase II, the enzyme responsible for the supercoiling of 
DNA. Mitoxantrone forms a stable complex with the enzyme, inhibiting its activity and 
causing DNA breakage and cell death.48, 58, 59, 62-64 
 
Hundreds of analogues of mitoxantrone have been synthesised in the search for a 
more active and less toxic drug. Compounds containing the anthraquinone skeleton 
with modified side chains have produced several positive results.59 DNA cleavage 
upon irradiation has been shown to be catalysed by cationic anthraquinones 
containing ammonium-substituted side chains (Figure 1.5). There are two distinct 
pathways by which the strand cleavage can be initiated. The excited quinones can 
either cause electron transfer from a nearby DNA base, or they can abstract a 
hydrogen atom from the deoxyribose component of the nucleic acid backbone. 
Regardless of the cleavage pathway, the anthraquinone is regenerated to its ground 
state, fully oxidised form and appears to be able to cycle indefinitely through this 
catalytic process. Hence, repeated use of anthraquinones as robust photonucleases 
for extended periods of time as small molecules or tethered to DNA recognition 
elements is a possibility. It was also found that anthraquinones containing the 
ammonium chain substituted in the 1-position of the anthraquinone ring did not 
cause DNA cleavage, even after prolonged periods of irradiation. However, those 
substituted in the 2-position of the anthraquinone skeleton, are efficient strand 
cleavers. The DNA binding of the 1-substituted anthraquinones is significantly weaker 
than their 2-substituted analogues.65  
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Figure 1.5:  The structures of the cationic anthraquinone derivatives.65 
 
Studies on related anthraquinone analogues have produced similar results. These 
anthraquinone analogues, shown in Figure 1.6, were found to produce GG-selective 
DNA cleavage. The dominant pathway by which this occurs is electron transfer from a 
DNA base to the excited intercalated anthraquinone. Some excited non-intercalated 
anthraquinones are also able to cause DNA cleavage. This occurs spontaneously, in a 
non-selective fashion when the excited anthraquinone abstracts a hydrogen atom 
directly from the deoxyribose backbone of the DNA.66 
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Figure 1.6:  The anthraquinone derivatives studied by Breslin et al66  for their 
potential as light-activated agents that initiate DNA cleavage. 
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The quinone skeleton of anthraquinone compounds is believed to have intrinsic 
hypoxic selectivity, that is, in regions of low oxygen tension found in many solid 
tumours the compound is reduced to its active form. The bioreductive activation cycle 
for quinones is shown in Figure 1.7.  
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Figure 1.7:  The quinone bioreductive cycle. 
 
The cellular tumour environment is known to have high bioreductive enzyme activity 
relative to normal tissues. Such enzymes can cause one or two-electron reduction of 
the quinone skeleton to the semiquinone free radical or the hydroquinone, 
respectively. The one-electron reduction to the semiquinone radical can be reversed 
in the presence of molecular oxygen to regenerate the quinone, and also form the 
superoxide anion.67-70 The superoxide radicals can subsequently produce DNA 
lesions, peroxidative damage to membrane lipids, alteration of subcellular 
organelles, etc, either directly or following conversion to hydroxy radicals.64, 71 The 
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semiquinone radicals can react with lipids, macromolecules and thiols to cause cell 
damage.64 In the absence of oxygen (that is, in a hypoxic environment) the 
semiquinone will be the predominant species. The toxicity of the semiquinone in 
hypoxic tissue should far exceed the damage caused by superoxide formation in well-
oxygenated tissue.69 The dose-limiting cardiotoxicity of doxorubicin is believed to 
partly be due to such damaging redox cycling.69 
 
Other anthraquinone derivatives possess hypoxic selectivity predominantly by virtue 
of their side chains. Compound (12) is one such example that was found to be active 
against hypoxic cells. Upon reduction in hypoxic conditions, compound (13), a potent 
topoisomerase II inhibitor and tight DNA binding agent, is formed.70, 72  
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Figure 1.8:  Under hypoxic conditions, compound (12) is converted to compound 
(13), a potent topoisomerase II inhibitor.  
 
The antiviral antibiotics netropsin and distamycin are known to selectively bind to AT-
rich sequences of DNA.49 This property has been utilised in attempts to produce 
sequence selective DNA binding agents. Helissey et al covalently linked these drugs 
to an anthraquinone moiety believed to be capable of DNA intercalation and 
photocleavage. The presence of the anthraquinone did not alter the sequence 
specific recognition properties of the drug, yet the DNA cleavage was found to be 
nonspecific in most cases.49 Boitte et al conducted a similar study involving the 
attachment of two netropsin moieties to each of the side chains of mitoxantrone. This 
conjugate retained the AT sequence specificity characteristics of netropsin, rather 
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than the GC sequence selectivity of mitoxantrone. This has been attributed to the 
exocyclic 2-amino group of guanine, which hinders the access of the netropsin moiety 
into the minor groove and in turn interferes with the intercalation of the 
anthraquinone ring. This conjugate molecule is less cytotoxic than mitoxantrone, and 
yet more growth-inhibitory than netropsin.59 
 
1.7 Platinum - intercalator complexes 
 
DNA is the main cellular target of the chemotherapeutic agent, cisplatin. Cisplatin is 
believed to exert its toxic effects by binding to DNA via inert coordination bonds to the 
N7 atoms of guanine or adenine.73 Hence the complex resides in the major groove of 
the DNA, interfering with normal cellular functions such as replication and 
transcription of DNA.13 One strategy to improve upon the clinical performance of 
cisplatin involves attachment of a platinum moiety to a group possessing intrinsic 
affinity for DNA,74, 75 such as an intercalator.  
 
A platinum-intercalator conjugate generally consists of a platinum centre tethered to 
an intercalator through a flexible linker chain and a stable bond to the metal centre. 
For the conjugate to be biologically active it will ideally remain intact under biological 
conditions, or until the binding of either of the components to DNA. A further 
requirement is that the two components remain functionally interdependent and the 
conjugate is able to both intercalate and platinate DNA. In addition, the platinum 
centre must contain at least one labile group that is able to react with a DNA 
nucleobase nitrogen atom to form a stable coordinative bond.43 
 
It is hypothesised that the intercalating moiety of such a platinum-intercalator 
conjugate will rapidly transport the platinum moiety to the vicinity of its DNA target, 
potentially minimising reactions with biomolecules76 and perhaps hindering efflux of 
the complexes from the cell. Thus the platinum centre may be held within the cell for 
sufficient time to allow it to exert its anticancer effects.32 Side reactions have been 
implicated in the deactivation of cisplatin,7-9, 11, 77 the adverse side effects associated 
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with cisplatin chemotherapy,6-11 and the resistance of tumours towards platinum-
based drugs.13-16 In addition, these novel platinum complexes may bind to DNA with 
different kinetics, mechanism or sequence specificity as compared to cisplatin, thus 
potentially overcoming cisplatin resistance.74, 76, 78, 79 Several platinum-intercalator 
complexes have been studied and a number have been shown to possess many of 
the hypothesised advantages over cisplatin. These studies have also been motivated 
by the fact that cisplatin is often administered in combination with intercalative drugs 
such as actinomycin and adriamycin.80-82 Consequently, tethering of the two regimes 
into a single drug may further enhance synergistic effects.  
 
1.7.1 Increased rate of DNA reaction  
 
Platinum phenanthridinium complexes (see Figure 1.9) have been shown to damage 
DNA more rapidly than cisplatin, with some requiring only 30 min to produce the 
same DNA damage as 18 hr incubation with cisplatin. Complexes with shorter 
polymethylene chains generally resulted in more extensive DNA damage.76 
Observations in intact human cancer (HeLa) cells were similar, with more efficient 
DNA damage produced by complexes with shorter linker chains, and up to a 6-fold 
enhancement of the rate of DNA damage compared to cisplatin. The complexes also 
showed good antitumour activity in mice bearing P388 wild-type leukaemia.83  
 
(14a):  n = 3
(14b):  n = 5
(14c):  n = 8
(14d):  n = 10
N+
(CH2)n NH NH2
Pt
Cl Cl
Cl
 
Figure 1.9: Structures of the platinum(II) phenanthridinium complexes. 
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Intercalator-tethered phenazine-1-carboxamide platinum(II) complexes ([PtCl2L], 
where L are phenazine ligands with varying lengths of polymethylene linker chain, 
see Figure 1.10), have been shown to increase the rate and extent of DNA platination 
as compared to [PtCl2(en)], even in the presence of thiols which are known to 
interfere with the interaction of cisplatin with DNA. Complexes with longer 
polymethylene linker chains (ie. n = 3, 4, 5) were more cytotoxic than cisplatin, 
[PtCl2(en)], or the ligands on their own. Molecular models reveal that complexes with 
polymethylene chains of length longer than n = 2 allow for both platination and 
intercalation to take place simultaneously and hence cause a large extent of DNA 
unwinding. The platinum binds covalently to DNA bases while the intercalator lies in 
the DNA major groove.78, 84 
 
N
N
N
H
(CH2)nO NH NH2
Pt
Cl Cl
(15a):  n = 2
(15b):  n = 3
(15c):  n = 4
(15d):  n = 5
 
Figure 1.10: Structures of the platinum(II) phenazine carboxamide complexes. 
  
1.7.2 Activity in cisplatin-resistant cell lines  
 
Many platinum-acridine complexes have been shown to possess activity in cisplatin-
resistant cells. For example, 9-anilinoacridine platinum complexes, based on ethane-
1,2-diamine and propane-1,3-diamine tethered intercalators, have been studied 
(Figure 1.11). Those based on ethane-1,2-diamine had similar in vitro toxicities 
against wild type P388 leukemia and cisplatin resistant P388 cell lines, and those 
based on propane-1,3-diamine were approximately 8-fold more active in the resistant 
line. However, the cytotoxicities were not significantly greater than the corresponding 
ligands in isolation. In contrast, the standards (cisplatin, ethane-1,2-diamine and 
CHAPTER 1:  Introduction 
 18  
propane-1,3-diamine platinum complexes) were approximately 10 times less active 
against the resistant cell line compared to the wild type line. Most of the intercalator 
complexes were found to have no in vivo activity against wild-type P388 leukaemia. It 
was suggested that the intercalator complexes may bind so as to direct the platinum 
away from the major groove of DNA. Hence it would not be possible for simultaneous 
platination and intercalation to be occurring. They conclude that future studies 
should involve complexes of varying topologies and improved solubilities.85  
 
HN
(CH2)n NH
Pt
NH2
Cl Cl
N
(16a):  n = 2
(16b):  n = 3
(16c):  n = 4
(16d):  n = 5
 
N
R R'
NH
(CH2)n
NH2
Pt
Cl
NH2 Cl
(17a): n = 1, R = R' = H
(17b): n = 2, R = R' = H
(17c): n = 3, R = R' = H
(17d): n = 4, R = R' = H
(17e): n = 5, R = R' = H
(17f): n = 3, R = OMe
                     R' = CONH(CH
2
)NMe
2
 
Figure 1.11: Structures of the 9-anilinoacridine platinum(II) complexes. (16a-d) are 
based on ethane-1,2-diamine and (17a-f) are based on propane-1,3-diamine. 
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Acridine carboxamide derivatives of [PtCl2(en)] have also been studied. In general, 
they were found to be more active and cytotoxic than the free ligands, though they 
had similar potencies. The acridine-4-carboxamide platinum complexes were more 
cytotoxic than the acridine-2-carboxamides. The complexes displayed equal in vitro 
activity against wild-type and cisplatin-resistant P388 leukaemia cell lines, in contrast 
to cisplatin.86 The sequence specificity of DNA damage was determined in plasmid 
DNA and it was found that the most intense damage sites were similar to cisplatin, 
though the medium and weak damage sites displayed slight differences.87 Damage 
caused by two such complexes (Figure 1.12, (18) and (19)) was monitored in intact 
human cancer (HeLa) cells and directly compared to that in purified HeLa DNA. It was 
found that the position and relative intensity of damage was similar in both systems 
for the acridine-4-carboxamide complex studied, whilst damage caused by the 
acridine-2-carboxamide complex was undetectable. This correlated with antitumour 
activity in mouse models with the acridine-2-carboxamide complex displaying little 
activity compared to [PtCl2(en)] and the acridine-4-carboxamide complex.88  
 
N
N
H
NH
O
NH2
Pt
Cl Cl(18)
 
N
O N
H
NH NH2
Pt
Cl Cl
(19)
 
Figure 1.12: Structure of the acridine carboxamides with (18) showing a 2-
carboxamide complex and (19) showing a 4-carboxamide complex. 
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1.7.3 Alterations in DNA sequence specificity  
 
The DNA sequence specificity of the vast majority of platinum-intercalator complexes 
is dominated by the platinum centre due to its high selectivity for cross linking to runs 
of adjacent purine bases in the major groove of double stranded DNA. This results in 
DNA adduct profiles closely resembling those of cisplatin.43 More recently, platinum-
intercalator complexes that break away from this paradigm have been developed. For 
example, platinum 9-aminoacridinecarboxamide complexes react rapidly with DNA 
with different sequence specificity than that of cisplatin. Complexes with shorter 
chain lengths (n = 2, 3) exhibited DNA adducts significantly different from those of 
cisplatin. Those with longer chains (n = 4, 5) tended to closely resemble the 
sequence specificity of cisplatin, preferring runs of consecutive guanine bases. This 
was the first report to show altered DNA sequence specificity for a cisplatin 
analogue.74 The sequence selectivity was retained in intact human cells, although 
the specificity differences compared to cisplatin were less distinct in cells than in 
purified plasmid DNA.79 
 
Platinum-acridinylthiourea conjugates have recently been developed and found to 
have different sequence selectivity than cisplatin. The complexes were rationally 
designed such that the metal is unable to bind in the G-rich region of the major 
groove, the dominant sites at which cisplatin is known to bind. The minor groove 
directed intercalating agent is attached to the platinum centre through a thiourea 
sulfur. The coordination sphere of the platinum consists of one chloro leaving group, 
whilst the sulfur atom and bidentate amine should act as non-leaving groups. Thus 
cross-linking with purine bases on DNA should be prevented and only monofunctional 
covalent DNA adducts should be allowed to form, with sequence and groove 
specificity dominated by the intercalator. Upon reaction of one such complex (R1 = 
CH3, R2 = H, R3 = CH3, see Figure 1.13, (20)) with calf thymus DNA, a unique array of 
monofunctional adducts was formed, 80% of which were at guanine-N7, and 20% at 
adenine sites, most likely at the N3 position in the minor groove. Adenine damage 
sites are unprecedented in the biocoordination chemistry of platinum anticancer 
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complexes thus far and suggest that the intercalator, rather than the platinum 
moiety, dictates the platination sites in a significant proportion of adducts.43, 89 Such 
findings open the door for development of platinum drugs significantly different from 
those currently in use. The same complex has also demonstrated promising activity, 
with high potency in HL-60 leukaemia cells. Micromolar cytotoxicities were observed 
in the ovarian cell line 2008 and its cisplatin resistant variant, C13*. This indicated 
no advantage over the acridine ligand in isolation, though suggests that the complex 
is capable of partially circumventing acquired cisplatin resistance in vitro.90 A more 
recent study investigated the in vitro cytotoxicity of two related complexes (with 
various substitution patterns for R1 – R3, see Figure 1.13, (20)). They were found to 
have cytotoxicities in the low micromolar range, representing activity similar or 
superior to cisplatin in cisplatin sensitive and resistant A2780 ovarian cancer cells, 
lung cancer cells (NCI-H460), and colon cancer cells (RKO).91 
 
Pt
NH2
Cl S
H2N
N N
R1
R2 R3
N
H
NH
2+
(20)
 
Figure 1.13: Structure of the platinum-acridinylthiourea complexes, where R1, R2, R3 
= H or CH3.  
 
1.8 Platinum – anthraquinone complexes 
 
Platinum-anthraquinone complexes have been extensively studied. Attachment of a 
platinum complex to the amine group on the sugar of doxorubicin resulted in a 
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complex, (21), that possesses activity against cisplatin and adriamycin-resistant 
murine leukemias and activity comparable to that of adriamycin in solid tumours.92, 93  
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Figure 1.14: The adriamycin-Pt(II) complex (21) studied by Pasini.92 
 
Several complexes consisting of an anthraquinone linked to a platinum(II) moiety via 
an (aminoalkyl)amino side chain have been examined. Figure 1.15 shows the 
structures of such complexes. Structure activity guidelines have been established for 
this class of complex. It was found, in general, that platinum complexes of 
anthraquinones substituted in position 2 were significantly less potent than the 
analogous complexes that have been substituted in position 1. In fact, their activity 
was equal to or lower than that of the isolated ligands.80 The length of the alkyl chain 
linking the anthraquinone to the platinum moiety affected the activity of the complex. 
In complexes based upon [PtCl2(en)], (22), linker chains consisting of 2 or 3 three 
methylene groups endowed the complex with significant activity. Those with longer 
linker chains were 100-fold less potent.80, 94-96 Three such complexes, containing 
short linker chains, had in vitro and in vivo activity similar to that of cisplatin.95 These 
complexes were more active than the [PtCl2(en)] platinum species and the free ligand 
from which they were derived. In addition, they were also more active than a 1:1 
mixture of the intercalator ligand with [PtCl2(en)]. Hence chemically tethering the two 
moieties is preferable to administering the two components in isolation.95 The activity 
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of similar complexes based on cis-PtCl2 (23) was found to be quite low and 
unaffected by linker chain length.94  
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Figure 1.15: The platinum-anthraquinone complexes studied by Gibson and 
coworkers.80, 94-96 Complex (22) is a bidentate based upon [PtCl2(en)], complex (23) 
is a monodentate based upon cisplatin, and complex (24) is a platinum-
anthraquinone complex with platinum:anthraquinone ratio of 1:2. The complexes 
shown here have been substituted in the 1-position of the anthraquinone. The 2-
position is indicated on complex (22). 
 
Other variations on the structure of these anthraquinone intercalators have been 
attempted. Altering the structure of the linking atoms between the intercalator and 
the platinum moiety (an ether linkage rather than an NH group) resulted in little 
variation of activity.95, 96 Tethering multiple anthraquinone intercalators to each 
platinum atom resulted in lower in vitro cytotoxic activity of the 1:2 
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platinum:intercalator complex, (24), as compared to the corresponding 1:1 
complexes.95 
 
Gibson and coworkers have developed a series of platinum-anthraquinone 
complexes that are structurally different from the platinum-intercalator complexes 
studied previously (Figure 1.16, (25) and (26)). Rather than linking the 
anthraquinone in an essentially irreversible fashion to the platinum moiety, which is 
the case for the structures found in Figure 1.15, it was linked in such a way that it 
would dissociate from the molecule. The anthraquinone should act as a carrier 
molecule to deliver the active platinum moiety to its DNA target prior to dissociation 
into its separate constituents.94, 97 The free ligands were found to be moderately 
active and the corresponding platinum complexes were 10-fold more active. 
However, when compared to the analogous compounds where the anthraquinone 
was irreversibly linked to the platinum species, their potencies were approximately 
10-fold lower. Interestingly, there was no difference observed between the activity of 
the platinum species and the platinum-anthraquinone species. These observations 
may indicate that these compounds are ineffective carrier ligands, though low 
aqueous solubility may have contributed to their low activities.97 
 
 
 
